CliffBio
biologic

Spevigo

spesolimab-sbzo

Loss of exclusivityMarch 2036projected — 12-year biologic exclusivity estimate
CompanyLEO Pharma A/S

Drug detail

Brand nameSpevigo
Active ingredientspesolimab-sbzo
Strength150MG/ML
Dosage formInjection
RouteSubcutaneous
ModalityBiologic
FDA approvalMarch 2024
Marketing statusRx

More from LEO Pharma A/S

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Spevigo patent cliff — loss of exclusivity March 2036 | CliffBio